Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients

Name: Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients
Published: 2020
License: Public Domain

Pfizer · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

autoimmune-diseases safety ulcerative-colitis

ulcerative colitis, autoimmune diseases, immune system diseases, tofacitinib, molecular mechanisms of pharmacological action, jak inhibitor, safety, observational

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients

Related documents